An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens

Marta Sobas*, Pau Montesinos, Blanca Boluda, Teresa Bernal, Edo Vellenga, Josep Nomdedeu, Jose Gonzalez-Campos, Maria Chillon, Aleksandra Holowiecka, Jordi Esteve, Juan Bergua, Jose David Gonzalez-Sanmiguel, Cristina Gil-Cortes, M. Tormo, Olga Salamero, Felix Manso, Isolda Fernandez, Javier de la Serna, Maria-Jose Moreno, Manuel Perez-EncinasIsabel Krsnik, Josep-Maria Ribera, Lourdes Escoda, Bob Lowenberg, Miguel Angel Sanz, J. M. Beltran de Heredia, J. M. Hernandez, J. Arias, F. Ramos, A. Roman, J. de la Serna, S. Negri, C. Rayon, J. Esteve, F. J. Fernandez-Calvo, J. Diaz-Mediavilla, C. Gil, M. Tormo, M. Olave, E. Amutio, C. Pedro, A. Gorosquieta, M. Viguria, M. Zudaire, T. Molero, M. J. Sayas, R. Guardia, J. Martinez, M. R. de Groot, H. C. Schouten, PETHEMA Cooperative Grp, HOVON Cooperative Grp, PALG Cooperative Grp, GATLA Cooperative Grp

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1030-1035
Number of pages6
JournalLeukemia & Lymphoma
Volume60
Issue number4
DOIs
Publication statusPublished - 21 Mar 2019

Keywords

  • Acute promyelocytic leukemia
  • CD56
  • ATRA
  • chemotherapy
  • prognostic
  • relapse
  • PROGNOSTIC-FACTORS
  • CONSOLIDATION
  • INDICATOR
  • FAILURE
  • ADULT
  • RISK

Cite this